Benzinga | Jan 18, 2022 10:03AM EST

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $34

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $50 to $34.